217 related articles for article (PubMed ID: 20832405)
1. (18)F-FECNT: validation as PET dopamine transporter ligand in parkinsonism.
Masilamoni G; Votaw J; Howell L; Villalba RM; Goodman M; Voll RJ; Stehouwer J; Wichmann T; Smith Y
Exp Neurol; 2010 Dec; 226(2):265-73. PubMed ID: 20832405
[TBL] [Abstract][Full Text] [Related]
2. 18F-labeled FECNT: a selective radioligand for PET imaging of brain dopamine transporters.
Goodman MM; Kilts CD; Keil R; Shi B; Martarello L; Xing D; Votaw J; Ely TD; Lambert P; Owens MJ; Camp VM; Malveaux E; Hoffman JM
Nucl Med Biol; 2000 Jan; 27(1):1-12. PubMed ID: 10755640
[TBL] [Abstract][Full Text] [Related]
3. Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys.
Masilamoni GJ; Bogenpohl JW; Alagille D; Delevich K; Tamagnan G; Votaw JR; Wichmann T; Smith Y
Brain; 2011 Jul; 134(Pt 7):2057-73. PubMed ID: 21705423
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and Biological Evaluation of [
Cao S; Tang J; Liu C; Fang Y; Ji L; Xu Y; Chen Z
Mol Imaging Biol; 2021 Oct; 23(5):733-744. PubMed ID: 33851345
[TBL] [Abstract][Full Text] [Related]
5. Availability of dopamine transporters in heroin-dependent subjects: A
Xu S; Liu Y; Li Y; Deng Y; Yuan J; Lv R; Wang Y; Zhang G; Guo Z; Fu D; Zeng H; Han M; Liu X
Psychiatry Res Neuroimaging; 2017 May; 263():121-126. PubMed ID: 28376406
[TBL] [Abstract][Full Text] [Related]
6. Initial human PET imaging studies with the dopamine transporter ligand 18F-FECNT.
Davis MR; Votaw JR; Bremner JD; Byas-Smith MG; Faber TL; Voll RJ; Hoffman JM; Grafton ST; Kilts CD; Goodman MM
J Nucl Med; 2003 Jun; 44(6):855-61. PubMed ID: 12791810
[TBL] [Abstract][Full Text] [Related]
7. Quantification of dopamine transporter density with [18F]FECNT PET in healthy humans.
Nye JA; Votaw JR; Bremner JD; Davis MR; Voll RJ; Camp VM; Goodman MM
Nucl Med Biol; 2014 Mar; 41(3):217-22. PubMed ID: 24533985
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of novel halo and tosyloxy nortropane derivatives as efficient precursors for the one-step synthesis of the dopamine transporter PET ligand [(18)F]FECNT.
Pijarowska-Kruszyna J; Jaron AW; Kachniarz A; Kasprzak K; Kowalska A; Malkowski B; Demphel S; Dollé F; Mikolajczak R
J Labelled Comp Radiopharm; 2014 Mar; 57(3):148-57. PubMed ID: 24497079
[TBL] [Abstract][Full Text] [Related]
9. PET imaging of the dopamine transporter with 18F-FECNT: a polar radiometabolite confounds brain radioligand measurements.
Zoghbi SS; Shetty HU; Ichise M; Fujita M; Imaizumi M; Liow JS; Shah J; Musachio JL; Pike VW; Innis RB
J Nucl Med; 2006 Mar; 47(3):520-7. PubMed ID: 16513622
[TBL] [Abstract][Full Text] [Related]
10. Potential of [(18)F]beta-CFT-FE (2beta-carbomethoxy-3beta-(4-fluorophenyl)-8-(2-[(18)F]fluoroethyl)nortropane) as a dopamine transporter ligand: A PET study in the conscious monkey brain.
Harada N; Ohba H; Fukumoto D; Kakiuchi T; Tsukada H
Synapse; 2004 Oct; 54(1):37-45. PubMed ID: 15300883
[TBL] [Abstract][Full Text] [Related]
11. Semi-automated preparation of the dopamine transporter ligand [(18)F]FECNT for human PET imaging studies.
Voll RJ; McConathy J; Waldrep MS; Crowe RJ; Goodman MM
Appl Radiat Isot; 2005 Sep; 63(3):353-61. PubMed ID: 15985372
[TBL] [Abstract][Full Text] [Related]
12. Comparison of [18F]FDOPA, [18F]FMT and [18F]FECNT for imaging dopaminergic neurotransmission in mice.
Honer M; Hengerer B; Blagoev M; Hintermann S; Waldmeier P; Schubiger PA; Ametamey SM
Nucl Med Biol; 2006 Jul; 33(5):607-14. PubMed ID: 16843835
[TBL] [Abstract][Full Text] [Related]
13. Prenatal stress induces increased striatal dopamine transporter binding in adult nonhuman primates.
Converse AK; Moore CF; Moirano JM; Ahlers EO; Larson JA; Engle JW; Barnhart TE; Murali D; Christian BT; DeJesus OT; Holden JE; Nickles RJ; Schneider ML
Biol Psychiatry; 2013 Oct; 74(7):502-10. PubMed ID: 23726316
[TBL] [Abstract][Full Text] [Related]
14. Quantitative analysis of binding sites for 9-fluoropropyl-(+)-dihydrotetrabenazine ([¹⁸F]AV-133) in a MPTP-lesioned PD mouse model.
Chao KT; Tsao HH; Weng YH; Hsiao IT; Hsieh CJ; Wey SP; Yen TC; Kung MP; Lin KJ
Synapse; 2012 Sep; 66(9):823-31. PubMed ID: 22623146
[TBL] [Abstract][Full Text] [Related]
15. Validation of nigrostriatal positron emission tomography measures: critical limits.
Karimi M; Tian L; Brown CA; Flores HP; Loftin SK; Videen TO; Moerlein SM; Perlmutter JS
Ann Neurol; 2013 Mar; 73(3):390-6. PubMed ID: 23423933
[TBL] [Abstract][Full Text] [Related]
16. Increased DAT binding in the early stage of the dopaminergic lesion: a longitudinal [11C]PE2I binding study in the MPTP-monkey.
Vezoli J; Dzahini K; Costes N; Wilson CR; Fifel K; Cooper HM; Kennedy H; Procyk E
Neuroimage; 2014 Nov; 102 Pt 2():249-61. PubMed ID: 25108180
[TBL] [Abstract][Full Text] [Related]
17. In vivo measures of nigrostriatal neuronal response to unilateral MPTP treatment.
Tian L; Karimi M; Brown CA; Loftin SK; Perlmutter JS
Brain Res; 2014 Jul; 1571():49-60. PubMed ID: 24845719
[TBL] [Abstract][Full Text] [Related]
18. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
[TBL] [Abstract][Full Text] [Related]
19. In vitro autoradiography and in vivo evaluation in cynomolgus monkey of [18F]FE-PE2I, a new dopamine transporter PET radioligand.
Varrone A; Steiger C; Schou M; Takano A; Finnema SJ; Guilloteau D; Gulyás B; Halldin C
Synapse; 2009 Oct; 63(10):871-80. PubMed ID: 19562698
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
